First Time Loading...

Idera Pharmaceuticals Inc
NASDAQ:IDRA

Watchlist Manager
Idera Pharmaceuticals Inc Logo
Idera Pharmaceuticals Inc
NASDAQ:IDRA
Watchlist
Price: 7.225 USD -21.57% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

IDRA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indica... [ Read More ]

The intrinsic value of one IDRA stock under the Base Case scenario is 0.193 USD. Compared to the current market price of 7.225 USD, Idera Pharmaceuticals Inc is Overvalued by 97%.

Key Points:
IDRA Intrinsic Value
Base Case
0.193 USD
Overvaluation 97%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Idera Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IDRA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Idera Pharmaceuticals Inc

Provide an overview of the primary business activities
of Idera Pharmaceuticals Inc.

What unique competitive advantages
does Idera Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Idera Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Idera Pharmaceuticals Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Idera Pharmaceuticals Inc.

Provide P/S
for Idera Pharmaceuticals Inc.

Provide P/E
for Idera Pharmaceuticals Inc.

Provide P/OCF
for Idera Pharmaceuticals Inc.

Provide P/FCFE
for Idera Pharmaceuticals Inc.

Provide P/B
for Idera Pharmaceuticals Inc.

Provide EV/S
for Idera Pharmaceuticals Inc.

Provide EV/GP
for Idera Pharmaceuticals Inc.

Provide EV/EBITDA
for Idera Pharmaceuticals Inc.

Provide EV/EBIT
for Idera Pharmaceuticals Inc.

Provide EV/OCF
for Idera Pharmaceuticals Inc.

Provide EV/FCFF
for Idera Pharmaceuticals Inc.

Provide EV/IC
for Idera Pharmaceuticals Inc.

Show me price targets
for Idera Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Idera Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Idera Pharmaceuticals Inc?

What are the Net Income projections
for Idera Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Idera Pharmaceuticals Inc?

What are the EPS projections
for Idera Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Idera Pharmaceuticals Inc?

What are the EBIT projections
for Idera Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Idera Pharmaceuticals Inc?

Compare the revenue forecasts
for Idera Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Idera Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Idera Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Idera Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Idera Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Idera Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Idera Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Idera Pharmaceuticals Inc.

Provide ROE
for Idera Pharmaceuticals Inc.

Provide ROA
for Idera Pharmaceuticals Inc.

Provide ROIC
for Idera Pharmaceuticals Inc.

Provide ROCE
for Idera Pharmaceuticals Inc.

Provide Gross Margin
for Idera Pharmaceuticals Inc.

Provide Operating Margin
for Idera Pharmaceuticals Inc.

Provide Net Margin
for Idera Pharmaceuticals Inc.

Provide FCF Margin
for Idera Pharmaceuticals Inc.

Show all solvency ratios
for Idera Pharmaceuticals Inc.

Provide D/E Ratio
for Idera Pharmaceuticals Inc.

Provide D/A Ratio
for Idera Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Idera Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Idera Pharmaceuticals Inc.

Provide Quick Ratio
for Idera Pharmaceuticals Inc.

Provide Current Ratio
for Idera Pharmaceuticals Inc.

Provide Cash Ratio
for Idera Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Idera Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Idera Pharmaceuticals Inc?

What is the current Free Cash Flow
of Idera Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Idera Pharmaceuticals Inc.

Financials

Balance Sheet Decomposition
Idera Pharmaceuticals Inc

Current Assets 17.9m
Cash & Short-Term Investments 12m
Receivables 4.2m
Other Current Assets 1.6m
Non-Current Assets 83.2m
PP&E 544k
Intangibles 82.7m
Current Liabilities 21.4m
Accounts Payable 5.2m
Accrued Liabilities 10.1m
Other Current Liabilities 6.1m
Non-Current Liabilities 40.8m
Other Non-Current Liabilities 40.8m
Efficiency

Earnings Waterfall
Idera Pharmaceuticals Inc

Revenue
4.9m USD
Operating Expenses
-24.4m USD
Operating Income
-19.5m USD
Other Expenses
-3.8m USD
Net Income
-23.4m USD

Free Cash Flow Analysis
Idera Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IDRA Profitability Score
Profitability Due Diligence

Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

IDRA Solvency Score
Solvency Due Diligence

Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
43/100
Solvency
Score

Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IDRA Price Targets Summary
Idera Pharmaceuticals Inc

There are no price targets for IDRA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IDRA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IDRA Price
Idera Pharmaceuticals Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
+502%
5Y 5Y
+175%
10Y 10Y
-70%
Annual Price Range
7.225
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return 0.92%
Standard Deviation of Annual Returns 105.02%
Max Drawdown -96%
Shares Statistics
Market Capitalization 450.1m USD
Shares Outstanding 62 296 900
Percentage of Shares Shorted 1.04%

IDRA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Idera Pharmaceuticals Inc Logo
Idera Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

450.1m USD

Dividend Yield

0%

Description

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm designed and is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101.

Contact

PENNSYLVANIA
Exton
505 Eagleview Blvd Ste 212
+14843481600.0
http://www.iderapharma.com/

IPO

1996-01-25

Employees

13

Officers

Chief Financial Officer
Mr. John J. Kirby CPA
Chief Bus. Officer & Gen. Counsel
Mr. Bryant David Lim
CEO & Director
Mr. John Taylor
Chief Operating Officer
Mr. Daniel Salain
Chief Strategy Officer
Mr. Andy Jordan
Chief Medical Officer
Dr. Carl Kraus M.D.
Show More
Medical Director & Global Clinical Lead for Oncology
Dr. Shah Rahimian M.D., Ph.D.
Advisor
Dr. Joanna Caroline Horobin Ch.B, M.B.
Scientific Advisor
Dr. Sudhir Agrawal D.Phil., F.R.S.C.
Adviser
Mr. Louis J. Arcudi III, M.B.A., MBA
Show Less

See Also

Discover More
What is the Intrinsic Value of one IDRA stock?

The intrinsic value of one IDRA stock under the Base Case scenario is 0.193 USD.

Is IDRA stock undervalued or overvalued?

Compared to the current market price of 7.225 USD, Idera Pharmaceuticals Inc is Overvalued by 97%.